Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 215

recruiting
3 982
countries
28
conditions
2 106

2 729 trials match your criteria

Adrenogenital syndrome

Not recruiting

Study on the Effects of Tildacerfont and Hydrocortisone in Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone

Adrenogenital syndrome

Not recruiting

Study on Tildacerfont to Reduce Glucocorticoid Use in Adults with Classic Congenital Adrenal Hyperplasia

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone

Heart failure with reduced ejection fraction

Not recruiting

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin

Diffuse large B-cell lymphoma

Not recruiting

Study of Zilovertamab Vedotin with Drug Combination for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

COVID-19

Not recruiting

Study on the Effects of S-217622 for Adults Hospitalized with COVID-19

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Dermatomyositis

Not recruiting

Study on the Effects of GLPG3667 for Adults with Dermatomyositis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.